SPRO

Latest SEC Filings & News for SPRO

2 most recent filings and news items mentioning SPRO. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/SPRO/news?limit=20"

Pull SPRO filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
M&AJul 14, 2026Positive

Spero Therapeutics Licenses Anti-CD40L Antibody SP001 to Innovent

Spero Therapeutics entered into a global license agreement for the anti-CD40L antibody SP001 with Innovent Biologics. The deal potentially worth $1.1 billion aims to expand Spero's pipeline into autoimmune diseases.

View filing at SEC.gov →
LeadershipJun 30, 2026Neutral

Sera Prognostics announces new director compensation policy starting July 2026

Sera Prognostics adopted a new compensation policy with increased annual retainers set to begin July 1, 2026. The policy details specific fees for board roles and committee assignments, aligning director pay with industry standards.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.